Previous 10 | Next 10 |
Bausch Health Companies (NYSE: BHC ) initiated with Neutral rating and C$40 (7% upside) price target at Goldman Sachs. Shares up 2% premarket. More news on: Bausch Health Companies Inc., Centogene N.V., Galapagos NV, Healthcare stocks news, Stocks on the move, , Read more ....
- Appointment completes build-out of Revance’s commercial leadership team following submission of the Company’s Biologics License Application to the U.S. Food and Drug Administration for DaxibotulinumtoxinA for Injection (DAXI) - Revance Therapeutics, Inc. (Nasdaq: RVNC),...
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today announced the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) fo...
Healthcare Pulse Healthcare is at its all-time highs eclipsing the highs recorded a year earlier during the Oct-Nov 2018 period. Of course, if one looks at the broader market which has been recording such all-time highs since the summer of this year, it's understandable to shrug shoulders ...
The following slide deck was published by Revance Therapeutics, Inc. in conjunction with this Read more ...
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Stifel 2019 Healthcare Conference, in New York, NY. President and Chief Exec...
Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Credit Suisse 28th Annual Healthcare Conference, in Scottsdale, AZ. Chief Fi...
Image source: The Motley Fool. Revance Therapeutics (NASDAQ: RVNC) Q3 2019 Earnings Call Nov 04, 2019 , 4:30 p.m. ET Operator Continue reading
Revance Therapeutics, Inc. (RVNC) Q3 2019 Earnings Conference Call November 4, 2019 16:30 ET Company Participants Jeanie Herbert - Senior Director of IR & Corporate Communications Mark Foley - President & CEO Tobin Schilke - CFO & Principal Accounting Officer Abhay ...
News, Short Squeeze, Breakout and More Instantly...
Revance Therapeutics Inc. Company Name:
RVNC Stock Symbol:
NASDAQ Market:
Revance Therapeutics Inc. Website:
Conference Call Scheduled for Thursday, August 8, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced that the company will release second quarter 2024 financial results on Thursday, August 8, 2024, after the close of market. Revance will host a corresp...
- Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. - DAXXIFY® net revenue of $22.1 million, after a reduction of $2.0 million related to a consumer coupon program. - Toxin market share increased from 3.0% in Q4’23 to 3...